Craneware
Market Cap
UK£709.9m
Last Updated
2021/06/23 22:05 UTC
Data Sources
Company Financials +
Executive Summary
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with solid track record and pays a dividend.
Similar Companies
Share Price & News
How has Craneware's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CRW is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CRW's weekly volatility (7%) has been stable over the past year.
Market Performance
7 Day Return
-2.3%
CRW
-1.4%
GB Healthcare Services
-1.3%
GB Market
1 Year Return
22.9%
CRW
29.6%
GB Healthcare Services
19.5%
GB Market
Return vs Industry: CRW underperformed the UK Healthcare Services industry which returned 28.5% over the past year.
Return vs Market: CRW exceeded the UK Market which returned 17.8% over the past year.
Shareholder returns
| CRW | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.3% | -1.4% | -1.3% |
| 30 Day | -19.2% | -9.5% | 0.5% |
| 90 Day | 3.1% | 1.2% | 6.7% |
| 1 Year | 24.4%22.9% | 31.8%29.6% | 25.3%19.5% |
| 3 Year | 5.3%1.7% | 25.2%19.0% | 13.8%0.7% |
| 5 Year | 192.8%174.8% | 80.5%64.1% | 48.8%20.7% |
Long-Term Price Volatility Vs. Market
How volatile is Craneware's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Co-Founder Keith Neilson Just Bought A Handful Of Shares In Craneware plc (LON:CRW)3 weeks ago | Simply Wall St
Is Craneware plc's (LON:CRW) Recent Stock Performance Influenced By Its Fundamentals In Any Way?1 month ago | Simply Wall St
Here's Why I Think Craneware (LON:CRW) Is An Interesting StockValuation
Is Craneware undervalued compared to its fair value and its price relative to the market?
46.33x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CRW (£21.5) is trading above our estimate of fair value (£6.15)
Significantly Below Fair Value: CRW is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CRW is poor value based on its PE Ratio (46.5x) compared to the European Healthcare Services industry average (45.4x).
PE vs Market: CRW is poor value based on its PE Ratio (46.5x) compared to the UK market (25.2x).
Price to Earnings Growth Ratio
PEG Ratio: CRW is poor value based on its PEG Ratio (3.8x)
Price to Book Ratio
PB vs Industry: CRW is overvalued based on its PB Ratio (11x) compared to the GB Healthcare Services industry average (6x).
Future Growth
How is Craneware forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
12.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRW's forecast earnings growth (12.1% per year) is above the savings rate (0.9%).
Earnings vs Market: CRW's earnings (12.1% per year) are forecast to grow slower than the UK market (17.3% per year).
High Growth Earnings: CRW's earnings are forecast to grow, but not significantly.
Revenue vs Market: CRW's revenue (7.2% per year) is forecast to grow faster than the UK market (5.3% per year).
High Growth Revenue: CRW's revenue (7.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRW's Return on Equity is forecast to be low in 3 years time (9.6%).
Past Performance
How has Craneware performed over the past 5 years?
9.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CRW has high quality earnings.
Growing Profit Margin: CRW's current net profit margins (23.5%) are higher than last year (21.4%).
Past Earnings Growth Analysis
Earnings Trend: CRW's earnings have grown by 9.8% per year over the past 5 years.
Accelerating Growth: CRW's earnings growth over the past year (13.4%) exceeds its 5-year average (9.8% per year).
Earnings vs Industry: CRW earnings growth over the past year (13.4%) underperformed the Healthcare Services industry 19.5%.
Return on Equity
High ROE: CRW's Return on Equity (23.9%) is considered high.
Financial Health
How is Craneware's financial position?
Financial Position Analysis
Short Term Liabilities: CRW's short term assets ($72.6M) exceed its short term liabilities ($48.2M).
Long Term Liabilities: CRW's short term assets ($72.6M) exceed its long term liabilities ($1.6M).
Debt to Equity History and Analysis
Debt Level: CRW is debt free.
Reducing Debt: CRW has not had any debt for past 5 years.
Debt Coverage: CRW has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CRW has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Craneware current dividend yield, its reliability and sustainability?
1.12%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CRW's dividend (1.12%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.27%).
High Dividend: CRW's dividend (1.12%) is low compared to the top 25% of dividend payers in the UK market (4.04%).
Stability and Growth of Payments
Stable Dividend: CRW's dividends per share have been stable in the past 10 years.
Growing Dividend: CRW's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (53.6%), CRW's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: CRW's dividends in 3 years are forecast to be covered by earnings (50.7% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
10.4yrs
Average management tenure
CEO
Keith Neilson (51 yo)
22.42yrs
Tenure
US$390,225
Compensation
Mr. Keith Neilson co-founded Craneware PLC in 1999 and has served as its Chief Executive Officer ever since. Keith’s direction has helped Craneware to win multiple prestigious awards in such areas as inter...
CEO Compensation Analysis
Compensation vs Market: Keith's total compensation ($USD390.23K) is below average for companies of similar size in the UK market ($USD961.48K).
Compensation vs Earnings: Keith's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: CRW's management team is seasoned and experienced (10.4 years average tenure).
Board Members
Experienced Board: CRW's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CRW insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.7%.
Top Shareholders
Company Information
Craneware plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Craneware plc
- Ticker: CRW
- Exchange: AIM
- Founded: 1999
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: UK£709.913m
- Shares outstanding: 33.02m
- Website: https://public.craneware.com
Number of Employees
Location
- Craneware plc
- 1 Tanfield
- Edinburgh
- EH3 5DA
- United Kingdom
Listings
Biography
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Chargemaster Tool...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/06/23 22:05 |
| End of Day Share Price | 2021/06/23 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.